View Older Stories
-
Piper Defending UNH: 'We would be buyers of the stock into 3Q26'
-
Evercore: 'Big positive for HUM, modestly positive for UNH, and slightly negative for CVS and ELV'
-
Humana (HUM) call put ratio 1 call to 1.2 puts into CMS release of latest Star ratings
-
Humana (HUM) call put ratio 1 call to 1.2 puts into CMS release of latest Star ratings
-
Baird Upgrades Humana (HUM) to Outperform
-
Humana soars, Alignment Healthcare sinks on Medicare rating changes
-
After-Hours Movers: T, VZ, TMUS, SPCX, HUM, ALHC, CVS, CLOV, UNH, AXP
-
Humana soars, Alignment Healthcare sinks around Part D Star Ratings release
-
Humana (HUM) Surges 13%
-
Cantor Fitzgerald Upgrades Humana (HUM) to Overweight, 'A Strong 2027 Margin Year Bridges to an Inexpensive 2028 Multiple'
-
Jefferies raises Medicaid attrition forecast for August 2026
-
Humana surges: Barclays bets big on Medicare star ratings rebound
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald as Uncertainty Continues
-
Humana reaffirms 2026 earnings guidance ahead of investor meetings
-
Humana (HUM) PT Raised to $450 at Wolfe Research
-
Humana and HealthStream partner on Indiana home care workforce
-
Humana names James Holland as Medicaid president, effective Aug. 17
-
Morgan Stanley Upgrades Humana (HUM) to Equalweight
-
Piper Sandler Upgrades Humana (HUM) to Overweight
-
Humana (HUM) PT Raised to $471 at Guggenheim
-
Raymond James Downgrades Humana (HUM) to Market Perform
-
Evercore ISI Upgrades Humana (HUM) to Outperform
-
BofA Securities Upgrades Humana (HUM) to Buy, 'The path to $45 EPS power by 2028'
-
Humana (HUM) Tops Q2 EPS by 38c, Beats on Revenue
-
Humana seen posting stronger Q2 as Medicare Advantage margins improve
-
Humana (HUM) PT Raised to $410 at BofA Securities
-
Humana (HUM) call put ratio 1.5 calls to 1 put as share price up 3.7%
-
Humana (HUM) PT Raised to $300 at Cantor Fitzgerald as Q/Q Enrollment Grows
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald: Positive on Medicaid Exposure
-
UBS Reiterates Neutral Rating on Humana (HUM) as Guidance Reaffirmed
-
UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald on $30B RFP Medicaid Award
-
Humana to sell minority stake in Gentiva for $900 million
-
RBC Capital on Humana (HUM): 'We are incrementally more confident in the company's medical cost trends'
-
Humana reaffirms FY 2026 earnings guidance of at least $9 adjusted EPS
-
Deutsche Bank Upgrades Humana (HUM) to Buy
-
Humana completes $1.5 billion pre-capitalized trust securities offering
-
Wolfe says Elevance Health has most conservative Medicaid enrollment guidance
-
Humana commits over $1 million to Louisiana health initiatives
-
Humana (HUM) PT Raised to $254 at Piper Sandler
-
Humana (HUM) PT Raised to $288 at Bernstein SocGen Group
-
Humana (HUM) PT Raised to $269 at Guggenheim
-
Humana (HUM) PT Raised to $262 at UBS
-
Humana (HUM) PT Raised to $267 at BofA Securities
-
Humana (HUM) PT Raised to $246 at RBC Capital
-
Humana (HUM) PT Raised to $250 at Evercore ISI
-
Humana (HUM) PT Raised to $290 at Mizuho
-
Bernstein SocGen Group Reiterates Outperform Rating on Humana (HUM) after earnings
-
Humana (HUM) Tops Q1 EPS by 11c; reaffirms guidance


